BioSpace News Archive

Oncocyte Corporation (Nasdaq: OCX), today announced that its management team will participate at the Lake Street 6th Annual Best Ideas Growth Conference on Wednesday, September 14, 2022 at the Yale Club in New York City, NY.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September.

Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, announced results for its second quarter ended July 31, 2022.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), today announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to take place in-person in New York and virtually September 12th-14th 2022.

Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.

Applied BioMath (www.appliedbiomath.com), today announced the speaker lineup for the Quantitative Systems Pharmacology (QSP) Summit occurring September 15, 2022 at Le Meridien Boston Cambridge in Cambridge, MA.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 29 individuals hired by Sarepta in August 2022.

GenScript Biotech, the world’s leading biotech company, today announces its annual results as of June 30, 2022.